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Abstract Oncogenic osteomalacia is a rare paraneo-
plastic syndrome characterized by renal phosphate excre-
tion, hypophosphatemia, and osteomalacia. This
syndrome is often caused by tumors of mesenchymal
origin. Patients with oncogenic osteomalacia have abnor-
mal bone mineralization, resulting in a high frequency of
fractures. Tumor resection is the treatment of choice, as
it will often correct the metabolic imbalance. Although
oncogenic osteomalacia is a potentially curable disease,
diagnosis is difficult and often delayed because of the
small size and sporadic location of the tumor. Bone
scintigraphy and radiography best characterize osteoma-
lacia; magnetic resonance imaging findings are nonspe-
cific. Here, we report a case of oncogenic osteomalacia
secondary to a phosphaturic mesenchymal tumor that
was successfully detected by 18F-fluorodeoxyglucose
positron emission tomography/computed tomography
(18F-FDG PET/CT). This case illustrates the advantages
of 18F-FDG PET/CT in detecting the occult mesenchymal
tumor that causes oncogenic osteomalacia.
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Introduction
Oncogenic osteomalacia is a rare paraneoplastic syndrome
associated with benign mesenchymal tumors, with clinical
features mimicking those of X-linked or autosomal-
dominant hereditary hypophosphatemic rickets. Oncogenic
osteomalacia is characterized by severe hypophosphatemia
and hyperphosphaturia. The tumors that are frequently
related to oncogenic osteomalacia are a rare class of
phosphaturic mesenchymal tumors of mixed connective
tissue origin [1].
It is well known that surgical removal of the mesenchy-
mal tumors relieves the symptoms and signs of osteoma-
lacia in oncogenic osteomalacia, and phosphate levels
return to normal levels within 2–3 days after surgery [2].
Because oncogenic osteomalacia is potentially curable after
tumor resection, it is of great importance to detect occult
mesenchymal tumors in patients with unexplained osteo-
malacia. To date, there are no standard methods for
detecting occult tumors causing oncogenic osteomalacia.
Computed tomography (CT) and magnetic resonance
imaging (MRI) are often non-contributory in detecting
mesenchymal tumors [3–5]. Bone scintigraphy or radiog-
raphy only reveals the osteomalacia and rarely detects the
mesenchymal tumor causing the syndrome [6, 7]. Somato-
statin receptor expression is elevated in mesenchymal
tumors, and it has been reported that 111In-pentetreotide or
octreotide scintigraphy was useful in some cases [8–10].
However, somatostatin receptor imaging was not contribu-
tory in another report [11].
To the best of our knowledge, only a few case reports have
evaluated the feasibility of 18F-fluorodeoxyglucose positron
emission tomography (18F-FDG PET)/CT in detecting occult
H. J. Seo :Y. J. Choi :H. J. Kim :Y. H. Jeong :A. Cho :
J. H. Lee :M. Yun : J. D. Lee :W. J. Kang (*)
Division of Nuclear Medicine, Department of Radiology,
Yonsei University College of Medicine,
Seongsanno 250, Seodaemun-gu,
Seoul 120-752, Korea
e-mail: mdkwj@yuhs.ac
Nucl Med Mol Imaging (2011) 45:233–237
DOI 10.1007/s13139-011-0095-7
mesenchymal tumors in oncogenic osteomalacia [11–15].
Despite the benign nature of mesenchymal tumors, each case
report indicated that the mesenchymal tumor associated with
oncogenic osteomalacia exhibited relatively high 18F-FDG
uptake and was easily detected by 18F-FDG PET/CT. Here,
we report a case that emphasizes the value of 18F-FDG PET/
CT in identifying the occult mesenchymal tumor associated
with oncogenic osteomalacia.
Case Report
A 66-year-old woman presented with severe bone pain, gait
disturbance, and muscle weakness. The patient complained
of pain in both hips and lumbar spine combined with thigh
muscle weakness that had persisted for 2 years before
admission. One year prior to admission, the pain worsened
in the thighs, knees, and ankles. Progressive lower limb
weakness developed, and pain extended to the thorax,
elbows, and wrists. She did not have a family history of
bone disease or fractures. Clinical exams were essentially
normal excluding bone and muscular abnormalities. The
patient had lost 8 kg since the onset of symptoms.
Radiographs of the skeleton revealed bilateral femoral neck
fractures and osteopenia, which are suggestive of osteomala-
cia. Bone scintigraphy using 99mTc-hydroxymethylene
diphosphonate (HDP) demonstrated focally increased uptake
in both rib cages and diffuse increased uptake in the thoracic
and lumbar spines, pelvis, knees, ankles, shoulders, and left
elbow (Fig. 1). Electromyography revealed no definite
evidence of denervation potential or myopathy. Bone
densitometry revealed decreased bone mass in the lumbar
vertebrae (T-score=−3.1), whole hip (T-score=−3.6), and
femoral neck (T-score=−1.6).
Laboratory tests revealed marked hypophosphatemia
(1.4 mg/dL; normal range: 2.5–4.5 mg/dL), normal serum
calcium levels (9.3 mg/dL), and increased total alkaline
phophatase levels (394 IU/L; normal range: 38–115 U/L).
The serum level of osteocalcin was 33.12 ng/mL (normal
range: 7.6±0.5 ng/mL), and the plasma concentration of
25-OH D was normal (18.13 ng/mL). Serum parathyroid
hormone, protein electrophoresis, creatinine, and muscle
enzyme levels, liver and thyroid function tests, erythrocyte
sedimentation rate, and blood cell count were within normal
ranges on laboratory findings.
With the clinical diagnosis of hypophosphatemic osteo-
malacia, 18F-FDG PET/CT was performed to detect the
occult tumor causing osteomalacia. An 18F-FDG PET/CT
image was acquired according to routine protocols after the
injection of 370 MBq of 18F-FDG. 18F-FDG PET/CT
revealed an isolated focus of hypermetabolism in the left
ischium (Fig. 2). The standardized uptake value (SUV) of
the lesion was calculated to be 4.7. No other abnormal
finding was found in the rest of the imaged body.
Additional MRI confirmed the presence of a well-defined
ovoid tumor in the ischium with gadolinium enhancement
that measured 2.1×1.2 cm in diameter (Fig. 3). A
mesenchymal tumor of mixed connective tissue origin
was confirmed by histopathologic examination (Fig. 4). In
the histologic examination, a large number of small spindle
cells with vascular networks, which is suggestive of a
typical mesenchymal tumor of mixed connective tissue
origin, were noted.
Surgical excision was performed to remove the mesen-
chymal tumor. Final histopathology revealed a mesenchy-
mal tumor of mixed connective tissue origin. Special
PosteriorAnterior
Fig. 1 99mTc-HDP whole-body bone scan findings on admission.
Multifocal increased uptake in both rib cages due to pseudofracture
and fracture was noted. Symmetric uptake in two costochondral
junctions (rosary pattern) is shown. Increased uptake was observed on
both shoulders, left elbow, femoral necks, and knees. These findings
represent osteomalacia. There was no focal area of significantly
increased activity in the left ischium
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staining resulted in partial positive SMA, positive vimentin,
and negative ER, PR, TTF-1, inhibin, and calretinin,
consistent with oncogenic osteomalacia. FGF-23 staining
was not performed in this study.
Two days after tumor removal, serum phosphorus levels
normalized to 2.5 mg/dL, and a normal value was
maintained in follow-up studies. Bone pain and muscle
weakness were ameliorated 13 days after the operation. Six
months later, follow-up bone scintigraphy was performed to
evaluate the recovery of osteomalacia. Compared with
preoperative bone scintigraphy, the increased uptake in both
shoulders, knees, and ankles was markedly decreased, but
mild residual uptake in both ribs, femoral necks, and axial
spine was still noted (Fig. 5). The gait function was
improved, and the serum level of alkaline phosphate
decreased to 188 IU/L.
Discussion
Oncogenic osteomalacia is almost exclusively associated
with mesenchymal benign tumors, which are frequently
located in the bone. Oncogenic osteomalacia is difficult to
diagnose because the tumor is frequently small; addition-
ally, it can be located in any soft tissue or skeleton, and it
generally causes no pain symptoms. According to the
reported cases, difficulty in tumor detection results in a
considerable delay in diagnosis and a delay between the
Fig. 2 a–c 18F-FDG PET/CT
findings. 18F-FDG PET/CT
revealed the increased 18F-FDG
uptake in the left ischium
(arrow), and the maximum SUV
was calculated to be 4.7, which is
suggestive of bone tumor. There
was no abnormal 18F-FDG up-
take, suggestive of malignant
processes, in the rest of the
imaged body (a MIP image,
b coronal view, c axial view)
A B
Fig. 3 a, b Pelvic MRI findings. a Axial gadolinium-enhanced T1-
weighted fat-suppressed MR image, b axial T2-weighted MR image.
A 2.1-cm ovoid lesion was identified on the left ischium. T1-weighted
fat-suppressed MRI identified a chondroid matrix tumor with contrast
enhancement (a; white arrow). T2-weighted MR image revealed a
low-to-intermediate-signal-intensity tumor (b; black arrow)
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onset of symptoms and surgical resection of 5 years on
average [16]. In many cases, CT and MRI are not
contributory in diagnosing oncogenic osteomalacia [3]
because this tumor is often small, grows slowly, and
develops in unpredictable locations such as feet [17],
mandibular ramus [18], and frontal bone [19]. Previous
case reports suggested that 18F-FDG PET/CT is a useful
modality in detection of oncogenic tumors causing onco-
genic osteomalacia [11–15]. In the present report, the
mesenchymal tumor causing oncogenic osteomalacia was
easily detected by 18F-FDG PET/CT.
In our report, the patient had typical symptoms and signs
of oncogenic osteomalacia. However, initial diagnostic
studies including physical examination and radiography
failed to localize the tumor. During the follow-up period,
radiography revealed only osteopenia and pseudofracture.
The constellation of bone scan findings was consistent with
osteomalacia, but the tumor in the left ischium was not
localized, probably due to low-level bone turnover and
limited localization within bone marrow. The present study
demonstrated the limitations of conventional imaging
modalities in detecting occult mesenchymal tumors. 18F-
FDG PET/CT is advantageous in that it has a high lesion-
to-background ratio for mesenchymal tumors, can evaluate
the entire body in contrast to regional scanning by MRI,
and can visualize the tumor itself rather than reactive bone
formation as detected in bone scintigraphy.
Although mesenchymal tumors causing oncogenic oste-
omalacia have benign characteristics, it has been reported
that 18F-FDG uptake was relatively high, which allows 18F-
FDG PET/CT to be easily located. Our case presented with
an SUV of 4.7, which is slightly higher than that in the
literature. It may be because the mesenchymal tumor in this
case had high cellularity and a large vascular supply, which
were observed in the histologic examination. However, the
mechanism of high glucose uptake should be further
elucidated.
We report a case of oncogenic osteomalacia that was
easily localized by 18F-FDG PET/CT. We suggest that 18F-
FDG PET should be performed in patients with hypophos-
phatemic osteomalacia to localize occult tumors and to
allow for proper surgical resection.
PosteriorAnterior
Fig. 5 Follow-up 99mTc-HDP bone scintigraphy 6 months after
surgical removal of the tumor. Compared to the preoperative bone
scintigraphy, a decrease in intensity is observed in the entire skeleton.
Mild uptake is observed in both rib cages, axial spine, femoral necks,
knees, and ankles. These findings indicate a favorable treatment
response after tumor resection
Fig. 4 a, b Histopathologic examination with hematoxylin and eosin
staining. a Band-like short spindle cell proliferation infiltrated into
marrow space, and abundant small capillaries were present. A partial
shell of woven bone was also present (×40). b Cell proliferation with a
vascular network was prominent in the high-magnification image
(×200)
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